Pricing in Germany – Key Learnings for Optimizing Price Potential After the Introduction of
AMNOG
Reference3 articles.
1. Bonduelle D. Batscheider A. Tremmel Met al. (2018).Overview of German AMNOG dossiers with price analysis before and after early benefit assessment. Poster at 21st ISPOR Europe Barcelona Spain (10–14 November 2018). Value in Health Vol. 21 S3 PHP237.
2. “Market withdrawals” of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations